Jinhong Ren

As Korean biotechs advance from discovery toward clinical development, the transition often exposes critical gaps in technical standards and strategic planning. This workshop will provide actionable guidance on implementing global best practices for assay design, selectivity profiling, and translational alignment, while addressing the unique challenges faced by emerging TPD companies in Asia. Attendees will gain clarity on what global partners expect, how to structure industry standard compliant data packages, and how to better transition into the clinic.

Key Takeaways:

• Defining assay standards for TPD modalities to ensure mechanistic clarity, meet global expectations and strengthen confidence in clinical readiness
• Integrating hypothesis-driven development roadmaps to align discovery with translational milestones, reduce costly pitfalls and accelerate clinical data package preparation
• The discovery of clinical-stage BTK degrader, BGB-16673and overcoming on-target resistance from BTK inhibitors